Search results
Results from the WOW.Com Content Network
Belimumab is primarily used in people with systemic lupus erythematosus. When it was introduced in 2011, it was the first new drug approved to treat lupus in 56 years. [8] Sales rose to $31.2 million in the first quarter of 2012. [37] The total cost for the first year of treatment with belimumab is $28,000. [38]
If the FDA approves Leqembi subcutaneous maintenance dosing, Leqembi will be the only treatment for AD that can be administered subcutaneously at home using an autoinjector. The injection process ...
Lecanemab was jointly developed by Eisai and Biogen. It was granted accelerated approval for medical use in the United States in January 2023, [27] and fully approved by the FDA in July 2023. [24] [28] Lecanemab was approved for medical use in South Korea in May 2024, [29] and in Mexico in December 2024. [30]
Lecanemab was jointly developed by Eisai and Biogen. It was granted accelerated approval for medical use in the United States in January 2023, [7] and fully approved by the FDA in July 2023. [4] [8] Lecanemab was approved for medical use in South Korea in May 2024, [9] and in Mexico in December 2024. [10]
Pharmaceutical maker GlaxoSmithKline will begin a phase 3 clinical trial to judge lupus medication Benlysta's effectiveness in treating patients with ANCA-positive vasculitis. The trial, which ...
For premium support please call: 800-290-4726 more ways to reach us
[33] [34] The phase 3 clinical trials also reported infusion related reactions, amyloid-related imaging abnormalities and headaches as the most common side effects of Lecanemab. In July 2023 the FDA gave Lecanemab full approval for the treatment of Alzheimer's Disease [35] and it was given the commercial name Leqembi.
For premium support please call: 800-290-4726 more ways to reach us